Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON D GOLDMAN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1740436609
CMS profile
953859
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$11,764.44

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $7,019.30 11
Merck Sharp & Dohme LLC $3,120.14 2
Invivyd Inc $1,625.00 1

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON D GOLDMAN

NPI 1740436609 · CMS profile ID 953859

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740436609?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON D GOLDMAN, NPI 1740436609, CMS profile ID 953859. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740436609?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JASON D GOLDMAN, NPI 1740436609, CMS profile ID 953859. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740436609?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JASON D GOLDMAN, NPI 1740436609, CMS profile ID 953859, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1740436609?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $11,764.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $3,022.5010/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141566433 CMS
Invivyd Inc $1,625.0009/20/2024 Consulting Fee No dispute reported Delay: No
Change: CHANGED
06/30/2026 1147384290 CMS
Merck Sharp & Dohme LLC $97.6406/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141566435 CMS
Gilead Sciences, Inc. $18.1704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133826239 CMS
Gilead Sciences, Inc. $32.0104/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133826241 CMS
Gilead Sciences, Inc. $46.5904/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133826243 CMS
Gilead Sciences, Inc. $8.0004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869120 CMS
Gilead Sciences, Inc. $153.4804/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869122 CMS
Gilead Sciences, Inc. $1,276.2004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869124 CMS
Gilead Sciences, Inc. $48.0403/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133826233 CMS
Gilead Sciences, Inc. $48.1903/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133826235 CMS
Gilead Sciences, Inc. $122.4803/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133826237 CMS
Gilead Sciences, Inc. $766.1403/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869118 CMS
Gilead Sciences, Inc. $4,500.0002/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133608164 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $122.85 1
PY2021 $17,574.00 7
PY2022 $15,210.91 14
PY2023 $13,287.42 14
PY2024 $11,764.44 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $158,197.00 5
PY2024 Principal investigator $90,056.83 3
PY2023 Principal investigator $165,634.58 75
PY2022 Principal investigator $250,665.41 168
PY2021 Principal investigator $1,865,002.79 46
PY2020 Principal investigator $3,623,465.43 32
PY2019 Principal investigator $21,772.20 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

168 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 10/13/2022 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611221
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 08/22/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357925
Principal investigator 1 Gilead Sciences, Inc. $4,950.00 08/03/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 07/28/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611147
Principal investigator 1 Gilead Sciences, Inc. $3,850.00 07/25/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357919
Principal investigator 1 Gilead Sciences, Inc. $4,000.00 07/25/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357921
Principal investigator 1 Gilead Sciences, Inc. $9,000.00 07/18/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 07/11/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 07/11/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 07/11/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/11/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/11/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 07/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 07/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/20/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46,690.00 06/20/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/16/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/16/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/16/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/16/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/16/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/16/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,766.89 06/09/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 06/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611111
Principal investigator 1 Gilead Sciences, Inc. $2,400.00 05/09/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357913
Principal investigator 1 Gilead Sciences, Inc. $2,500.00 05/09/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 04/25/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938611109
Principal investigator 1 Gilead Sciences, Inc. $385.00 04/20/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.80 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.16 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $279.18 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.04 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54.00 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.16 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $256.50 04/07/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.80 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $256.50 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 03/24/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611065
Principal investigator 1 Gilead Sciences, Inc. $385.00 03/23/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.80 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $256.50 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.80 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $256.50 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $256.50 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.80 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $256.50 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.80 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 03/17/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938611047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 03/14/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/14/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/14/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/14/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.38 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.38 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.38 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.38 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.29 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.29 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,232.87 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.29 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.29 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.29 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.29 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,232.87 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,232.87 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.38 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.38 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.29 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,232.87 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,232.87 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,232.87 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,232.87 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,769.46 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.38 03/03/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938610857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $256.50 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.80 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.65 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 03/01/2022 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants No dispute reported 06/30/2026 938610893
Principal investigator 1 Gilead Sciences, Inc. $77,503.00 02/23/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357907
Principal investigator 1 Gilead Sciences, Inc. $500.00 02/16/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920357905